Disulfiram Efficacy in the Treatment of Alcohol Dependence: A Meta-Analysis
Open accessThe DOI matches its Crossref record; 69 of the 71 references it cites were found in a registry or an index; 1 of the 50 sources its claims cite were checked for support.
Abstract
BACKGROUND: Despite its success with compliant or supervised patients, disulfiram has been a controversial medication in the treatment of alcoholism. Often, study designs did not recognize a pivotal factor in disulfiram research, the importance of an open-label design. Our objectives are: (1) to analyze the efficacy and safety of disulfiram in RCTs in supporting abstinence and (2) to compare blind versus open-label studies, hypothesizing that blinded studies would show no difference between disulfiram and control groups because the threat would be evenly spread across all groups. METHODS AND FINDINGS: We searched PubMed, EMBASE and the Cochrane Central Register for RCTs on disulfiram use with alcoholics in comparison to any alcoholic control group. The primary outcome was defined by the authors of each trial. Additional analyses included: blind vs. open-label, with or without supervision, cocaine study or not, and type of control. Overall, the 22 included studies showed a higher success rate of disulfiram compared to controls Hedges'g = .58 (95%CI = .35-.82). When comparing blind and open-label RCTs, only open-label trials showed a significant superiority over controls g = .70 (95%CI = .46-.93). RCTs with blind designs showed no efficacy of disulfiram compared to controls. Disulfiram was also more effective than the control condition when compared to naltrexone g = .77, 95%CI = .52-1.02, to acamprosate g = .76, 95%CI = .04-1.48, and to the no disulfiram groups g = .43, 95%CI = .17-.69. LIMITS INCLUDE: (1) a population of 89% male subjects and (2) a high but unavoidable heterogeneity of the studies with a substantial I-square in most subgroups of studies. CONCLUSIONS: Blinded studies were incapable of distinguishing a difference between treatment groups and thus are incompatible with disulfiram research. Based on results with open-label studies, disulfiram is a safe and efficacious treatment compared to other abstinence supportive pharmacological treatments or to no disulfiram in supervised studies for problems of alcohol abuse or dependence.
Overview
CoChat Summary
TL;DR
This meta-analysis found that disulfiram was superior to controls in open-label randomized trials, but not in blinded trials, suggesting that blinding masks the key expectancy mechanism of the drug. It also found more adverse events with disulfiram, but no difference from controls in deaths or serious adverse events requiring hospitalization.
Key findings
- Across 22 RCTs and 2,414 subjects, disulfiram had a higher success rate than controls: Hedges’ g = 0.58 (95% CI 0.35–0.82); heterogeneity was I² = 72%. After trim-and-fill correction, the effect remained significant: g = 0.47 (95% CI 0.24–0.71).
- In the blind/open-label subgroup analysis, open-label trials showed benefit: g = 0.70 (95% CI 0.46–0.93), while blinded trials showed no efficacy: g = 0.01 (95% CI −0.29–0.32).
- With supervision, disulfiram was significantly superior to controls: g = 0.82 (95% CI 0.59–1.05; I² = 46%); without supervision it was not significant: g = 0.26 (95% CI −0.02–0.53).
- Compared with specific controls, disulfiram was superior to naltrexone (g = 0.77), acamprosate (g = 0.76), and no disulfiram (g = 0.43). It also showed a higher adverse-events rate ratio of 1.40 (95% CI 1.01–1.94).
Methods
- Systematic review and meta-analysis of randomized controlled trials comparing oral disulfiram with any control group in alcohol-dependent/abusing patients; databases searched were PubMed, EMBASE, Cochrane Central Register, plus manual search (last searches June–November 2012).
- Final sample included 22 studies published from 1973 to 2010; total analyzed sample was 2,414 subjects, with some studies involving comorbid cocaine dependence.
- Main analysis used Hedges’ g under a random-effects model, with subgroup analyses by blinding, supervision, cocaine vs non-cocaine studies, and control condition, plus funnel plots, trim-and-fill, leave-one-out sensitivity analyses, and meta-regression.
Limitations
- The paper states that the included studies had a high and unavoidable heterogeneity with substantial I² in most subgroups, and that there was a possible publication bias suggested by funnel-plot asymmetry in the overall and open-label analyses.
- The paper states a sample composition limitation: 89% male subjects, so generalizability to women is limited.
- Evident from the text: many studies were methodologically weak by Cochrane criteria—among the 22 studies, 6 met none of the six risk-of-bias criteria, and only 2 met four—and many outcomes were based on differing primary endpoints across trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
1 Valid · 0 Not valid · 21 Not checked · 74 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Compliance has been a serious impediment in disulfiram research in numerous studies [26], [27].”
§ Disulfiram Efficacy in the Treatment of Alcohol Dependence: A Meta-Analysis > Introduction
What the sources say
- Supportedcites [26] HM Pettinati, 2008, A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence, Addict Behav source
The Discussion states that taking fewer pills than prescribed 'has also been consistently reported in alcohol dependent populations for both disulfiram (Fuller, Rieckmann, McCarty, Smith et al., 2005)' and that 'typically disulfiram has had much higher nonadherence problems than naltrexone (De Witte et al., 2005; Fuller & Gordis, 2004; Suh et al., 2006)', i.e. a recurring problem credited to numerous studies. Results §3.2 adds that only 35.1% of patients received 80% or more of the possible disulfiram pills and that the modest adherence/exposure prevented meaningful post-hoc analyses of outcome, so compliance was indeed an impediment in this disulfiram trial. Together these support the paraphrase that compliance has been a serious impediment in disulfiram research. (LLM, conf=0.85)
- Not checked yetcites [27] RK Fuller, 1986, Disulfiram treatment of alcoholism. A Veterans Administration cooperative study, JAMA source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Disulfiram was also more effective than the control condition when compared to naltrexone g = .77, 95%CI = .52–1.02, to acamprosate g = .76, 95%CI = .04–1.48, and to the no disulfiram groups g = .43, 95%CI = .17–.69.”
§ Disulfiram Efficacy in the Treatment of Alcohol Dependence: A Meta-Analysis > Abstract > Methods and Findings
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Disulfiram was also more effective than the control condition when compared to naltrexone g = .77, 95%CI = .52–1.02, to acamprosate g = .76, 95%CI = .04–1.48, and to the no disulfiram groups g = .43, 95%CI = .17–.69.”
§ Disulfiram Efficacy in the Treatment of Alcohol Dependence: A Meta-Analysis > Abstract > Methods and Findings
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A visual inspection of the funnel plot revealed asymmetry, indicating a possible publication bias.”
§ Disulfiram Efficacy in the Treatment of Alcohol Dependence: A Meta-Analysis > Results > Disulfiram efficacy
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“I2 was 72%.”
§ Disulfiram Efficacy in the Treatment of Alcohol Dependence: A Meta-Analysis > Results > Disulfiram efficacy
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
51 more claims
Create a free account to see all 96 claims and to verify the 49 references still open.
- Probably not a substantial claim. 21
- It may state two separate claims as one. 24
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a meta-analysis of 22 studies, disulfiram demonstrated a higher success rate in promoting abstinence compared to placebo in open-label trials [52].”
From A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder (2024) · cites this paper as [52]
Experimental — accuracy not yet measured
Citations
Cites
Statistical power analysis for the behavioral sciences
(1990) · Computers, Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,269
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J. P. T., Green, S. R., & Higgins, J. P. T. (2008) · Cited by 7,171
Regier, D. A. (1990) · JAMA · doi:10.1001/jama.1990.03450190043026 · Cited by 3,962 · cited 1×
“Numerous studies have shown that the majority of patients who abuse cocaine also abuse alcohol, ranging from 50% to 90% [53,54,55,56,57,58].”
BackgroundAssessing Risk of Bias in Included Studies
Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch8 · Cited by 3,396
Regier, D. A., Farmer, M. E., Rae, D. S., et al. (1990) · PubMed · Cited by 1,913
Disulfiram treatment of alcoholism. A Veterans Administration cooperative study
Fuller, R. K. (1986) · JAMA · doi:10.1001/jama.256.11.1449 · Cited by 541
Disulfiram Treatment of Alcoholism: A Veterans Administration Cooperative Study
Fuller, R. K. (1986) · JAMA · doi:10.1001/jama.1986.03380110055026 · Cited by 431 · cited 10×
“In the larger study (n = 605) [27], only 20% of the 577 who completed the study were compliant.”
BackgroundInfluentialThe Development of a Questionnaire to Measure Severity of Alcohol Dependence *
Stockwell, T., Hodgson, R., Edwards, G., Taylor, C., & Rankin, H. (1979) · British Journal of Addiction to Alcohol & Other Drugs · doi:10.1111/j.1360-0443.1979.tb02415.x · Cited by 419
Carroll, K. M., Fenton, L. R., Ball, S. A., Nich, C., Frankforter, T. L., Shi, J., & Rounsaville, B. J. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.3.264 · Cited by 414 · cited 2×
“We were unable to obtain the baseline alcohol consumption for the sub sample of codependent patients in the Carroll et al study (2004) [43].”
MethodAlcoholism treatment by disulfiram and community reinforcement therapy
Azrin, N. H., Sisson, R. W., Meyers, R., & Godley, M. (1982) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/0005-7916(82)90050-7 · Cited by 411 · cited 2×
“Disulfiram has been used in the treatment of alcohol dependence with consistently successful results in individuals with high compliance or when medication intake has been directly supervised [1,2,3].”
Background
Research works printed but not linked: 2
- A De Sousa, 2009, An open label trial of naltrexone versus disulfiram in elderly patients with alcohol dependence, JPPS, 6, 85
- K Carroll, 2004, Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients, Archives of General Psychiatry, 61, 264, 10.1001/archpsyc.61.3.264 · DOI · Paper page
Cited by
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
Advances in the science and treatment of alcohol use disorder
Witkiewitz, K., Litten, R. Z., & Leggio, L. (2019) · Science Advances · doi:10.1126/sciadv.aax4043 · Cited by 592
Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review
Kranzler, H. R., & Soyka, M. (2018) · JAMA · doi:10.1001/jama.2018.11406 · Cited by 580
Connor, J. P., Haber, P. S., & Hall, W. D. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00122-1 · Cited by 389
Hazardous drinking and alcohol use disorders
MacKillop, J., Agabio, R., Feldstein Ewing, S. W., Heilig, M., Kelly, J. F., Leggio, L., Lingford-Hughes, A., Palmer, A. A., Parry, C. D., Ray, L., et al. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00406-1 · Cited by 215
“Notably, evidence of the effectiveness of disulfiram has been strongest in trials using witnessed or otherwise supervised administration (such as in collaboration with a spouse or partner), with limited benefits in unwitnessed administration 274,275 , due to low medication compliance.”
Impact of Alcohol Use Disorder Treatment on Clinical Outcomes Among Patients With Cirrhosis
Rogal, S., Youk, A., Zhang, H., Gellad, W. F., Fine, M. J., Good, C. B., Chartier, M., DiMartini, A., Morgan, T., Bataller, R., et al. (2020) · Hepatology · doi:10.1002/hep.31042 · Cited by 218
“Disulfiram inhibits acetaldehyde dehydrogenase, causing gastrointestinal symptoms, headache, and hypotension, when consumed with alcohol.(44) The potential for severe liver toxicity, hypotension, and psychiatric side effects may limit the use of disulfiram in patients with cirrhosis.”
BackgroundTreatment of alcohol use disorders in patients with alcoholic liver disease
Addolorato, G., Mirijello, A., Barrio, P., & Gual, A. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.029 · Cited by 197
“Data from open-label studies indicate a possible efficacy of disulfiram in AUDs [66].”
BackgroundAlcohol-Related Liver Disease: Basic Mechanisms and Clinical Perspectives
Liu, S.-Y., Tsai, I.-T., & Hsu, Y.-C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105170 · Cited by 183
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
“A meta-analysis of 22 RCTs found that disulfiram saw increased success rates compared to placebo in open-label studies only—blinded trials yielded no statistical significance between disulfiram and placebo [29].”
BackgroundBentzley, B. S., Han, S. S., Neuner, S., Humphreys, K., Kampman, K. M., & Halpern, C. H. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.8049 · Cited by 161
Prevention, screening, and treatment for heavy drinking and alcohol use disorder
Knox, J., Hasin, D. S., Larson, F. R. R., & Kranzler, H. R. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30213-5 · Cited by 141
Rose, A. K., & Jones, A. (2018) · Addiction · doi:10.1111/add.14191 · Cited by 137
State-of-the-art behavioral and pharmacological treatments for alcohol use disorder
Ray, L. A., Bujarski, S., Grodin, E., Hartwell, E., Green, R., Venegas, A., Lim, A. C., Gillis, A., & Miotto, K. (2019) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2018.1528265 · Cited by 137
Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review
Jones, J. L., Mateus, C. F., Malcolm, R. J., Brady, K. T., & Back, S. E. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00277 · Cited by 135
Rolland, B., Paille, F., Gillet, C., Rigaud, A., Moirand, R., Dano, C., Dematteis, M., Mann, K., & Aubin, H. (2016) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12489 · Cited by 120
“It is worth mentioning that the drug’s specific mode of action implies that double-blind designs are not adequate (41).”
Self-citationNew Australian guidelines for the treatment of alcohol problems: an overview of recommendations
Haber, P., Riordan, B. C., Winter, D. T., Barrett, L., Saunders, J., Hides, L. M., Gullo, M. J., Manning, V., Day, C., Bonomo, Y. A., et al. (2021) · The Medical Journal of Australia · doi:10.5694/mja2.51254 · Cited by 150
Alcohol Use Disorder Treatment: Problems and Solutions
Koob, G. F. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-031323-115847 · Cited by 145
Behavioral and neural processes in counterconditioning: Past and future directions
Keller, N. E., Hennings, A. C., & Dunsmoor, J. E. (2019) · Behaviour Research and Therapy · doi:10.1016/j.brat.2019.103532 · Cited by 115
Gabapentin for the treatment of alcohol use disorder
Mason, B. J., Quello, S., & Shadan, F. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1417383 · Cited by 104
“may comprise the primary mechanism of disulfiram’s deterrent effect, as opposed to the drug’s pharmacodynamic (PD) properties [15].”
Alcohol Use Disorder: Neurobiology and Therapeutics
Yang, W., Singla, R., Maheshwari, O., Fontaine, C. J., & Gil‐Mohapel, J. (2022) · Biomedicines · doi:10.3390/biomedicines10051192 · Cited by 140
“In these studies, control groups received either placebo, acamprosate, naltrexone, or no disulfiram, and success was defined as one of the following: total abstinence, proportion of abstinent days to treatment days, mean days of alcohol use, likelihood of no relapse, time to first heavy drinking day, or three or more…”
MethodOverview of Alcohol Use Disorder
Kranzler, H. R. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230488 · Cited by 132
Medications for alcohol use disorders: An overview
Akbar, M., Egli, M., Cho, Y.-E., Song, B.-J., & Noronha, A. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.11.007 · Cited by 96
Pharmacotherapy of alcoholism – an update on approved and off-label medications
Soyka, M., & Müller, C. A. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1349098 · Cited by 86
“), psychiatric, hepatic, and cardiac ones, as well as drug–drug interactions, and deaths associated with disulfiram use have been reported [56].”
BackgroundSoyka, M., Kranzler, H. R., Hesselbrock, V., Kasper, S., Mutschler, J., Möller, H.-J., & The WFSBP Task Force on Treatment Guidelines for Substance Use Disorders (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2016.1246752 · Cited by 85
“number of days drinking, time to first relapse) in a total of 22 RCTs found a significant overall effect for disulfiram (Skinner et al. 2014).”
BackgroundClinical management of the alcohol withdrawal syndrome
Day, E., & Daly, C. (2021) · Addiction · doi:10.1111/add.15647 · Cited by 104
Cheng, H.-Y., McGuinness, L. A., Elbers, R. G., MacArthur, G. J., Taylor, A., McAleenan, A., Dawson, S., López-López, J. A., Higgins, J. P. T., Cowlishaw, S., et al. (2020) · BMJ · doi:10.1136/bmj.m3934 · Cited by 78
Evidence-Based Pharmacotherapies for Alcohol Use Disorder
Fairbanks, J., Umbreit, A., Kolla, B. P., Karpyak, V. M., Schneekloth, T. D., Loukianova, L. L., & Sinha, S. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.01.030 · Cited by 87
“However, in a follow-up meta-analysis, success rates were only noted in open-label studies compared with blinded trials.(54)”
BackgroundResultInfluentialvan den Brink, W., Addolorato, G., Aubin, H., Benyamina, A., Caputo, F., Dematteis, M., Gual, A., Lesch, O., Mann, K., Maremmani, I., et al. (2018) · Addiction Biology · doi:10.1111/adb.12645 · Cited by 75
Self-citationAlcohol-Associated Liver Disease: Integrated Management With Alcohol Use Disorder
Arab, J. P., Addolorato, G., Mathurin, P., & Thursz, M. R. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.02.017 · Cited by 79
Bahji, A., Bach, P., Danilewitz, M., Crockford, D. N., Devoe, D. J. A., el‐Guebaly, N., & Saitz, R. (2022) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000992 · Cited by 92
“found no evidence of superiority in blinded studies, the findings from open-label studies suggested it was a safe and efficacious treatment.(28) However, in their meta-analysis,(28) all outcomes were pooled, whereas the present meta-analysis stratified outcomes by abstinence and heavy drinking.”
BackgroundResultReview article: pharmacotherapy for alcohol dependence – the why, the what and the wherefore
Goh, E. T., & Morgan, M. Y. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13965 · Cited by 87
“supervision, disulfiram is a safe and efficacious treatment compared to no treatment or to other pharmacological agents.(41) However, no evidence of efficacy was”
BackgroundMethodTargeting liver aldehyde dehydrogenase-2 prevents heavy but not moderate alcohol drinking
Guillot, A., Ren, T., Jourdan, T., Pawlosky, R. J., Han, E., Kim, S.-J., Zhang, L., Koob, G. F., & Gao, B. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908137116 · Cited by 68
Alcohol Use Disorder: The Role of Medication in Recovery
Mason, B. J., & Heyser, C. J. (2021) · Alcohol research · doi:10.35946/arcr.v41.1.07 · Cited by 81
Interactions between Food and Drugs, and Nutritional Status in Renal Patients: A Narrative Review
D’Alessandro, C., Benedetti, A., Di Paolo, A., Giannese, D., & Cupisti, A. (2022) · Nutrients · doi:10.3390/nu14010212 · Cited by 66
“Interestingly, that effect can also occur with other drugs, such as metronidazole, cephalosporins, sulfonylureas, chloramphenicol, griseofulvin, and quinacrine, which manifest a “disulfiram-like” reaction [103,104].”
BackgroundEffects of cannabidiol plus naltrexone on motivation and ethanol consumption
Viudez‐Martínez, A., García‐Gutiérrez, M. S., Fraguas‐Sánchez, A. I., Torres‐Suárez, A. I., & Manzanares, J. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14380 · Cited by 74
“To date, there are just three drug-based treatments approved for AUD by the Food and Drug Administration and the European Medicines Agency: naltrexone, disulfiram and acamprosate (Rosner et al., 2010; Jarosz et al., 2013; Skinner et al., 2014).”
BackgroundAldehyde dehydrogenase-2 as a therapeutic target
Kimura, M., Yokoyama, A., & Higuchi, S. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1690454 · Cited by 68
“A meta-analysis of 22 randomized controlled trials (RCTs) suggested that the success rate of disulfiram was significantly higher than that in controls in open-label trials, particularly under the conditions with supervision by family members, friends, clinic staff, and others [106].”
BackgroundYang, B.-Z., Balodis, I. M., Lacadie, C. M., Xu, J., & Potenza, M. N. (2016) · Journal of Behavioral Addictions · doi:10.1556/2006.5.2016.026 · Cited by 59
“For example, the drug disulfiram is effective in the treatment of alcohol and CD, possibly through effects on craving (Carroll et al., 2004; Skinner et al., 2014).”
BackgroundRubinsky, A. D., Chen, C., Batki, S. L., Williams, E. C., & Harris, A. H. S. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.07.016 · Cited by 57
“Based on recent meta-analyses of the efficacy of medications for AUD, the number needed to treat (NNT) to prevent return to any drinking ranged from 2 to 20 depending on the particular drug (Blodgett et al., 2014; Jonas et al., 2014; Skinner et al., 2014).”
MethodMedications for Alcohol Use Disorder.
Winslow, B. T., Onysko, M. K., & Hébert, M. (2016) · PubMed · Cited by 89
A sleeping giant: Suvorexant for the treatment of alcohol use disorder?
Campbell, E. J., Marchant, N. J., & Lawrence, A. J. (2018) · Brain Research · doi:10.1016/j.brainres.2018.08.005 · Cited by 59
WFSBP and IAWMH Guidelines for the treatment of alcohol use disorders in pregnant women
Thibaut, F., Chagraoui, A., Buckley, L., Gressier, F., Labad, J., Lamy, S., Potenza, M. N., Kornstein, S. G., Rondón, M. B., Riecher‐Rössler, A., et al. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2018.1510185 · Cited by 63
“Treatment with disulfiram is not recommended as first-line treatment despite its potential efficacy (Mutschler et al. 2013; Skinner et al. 2014).”
BackgroundTreatment-refractory substance use disorder: focus on alcohol, opioids, and cocaine
Soyka, M., & Mutschler, J. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.11.003 · Cited by 49
“However, evidence for efficacy is limited, at least in non-supervised settings; supervised treatment with disulfiram produces high effect sizes, making it an effective and well-established form of pharmacotherapy for relapse prevention in alcohol dependence (Skinner et al., 2014).”
BackgroundAgabio, R., Pani, P. P., Preti, A., Gessa, G. L., & Franconi, F. (2016) · European Addiction Research · doi:10.1159/000433579 · Cited by 48
Identification and Treatment of Alcohol Use Disorder
Haber, P. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2306511 · Cited by 64
New steps for treating alcohol use disorder
Campbell, E. J., Lawrence, A. J., & Perry, C. J. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4887-7 · Cited by 52
Alcohol use in opioid agonist treatment
Nolan, S., Klimas, J., & Wood, E. (2016) · Addiction Science & Clinical Practice · doi:10.1186/s13722-016-0065-6 · Cited by 47
“While two subsequent meta-analyses [71, 72] did demonstrate efficacy with the use of disulfiram when administered in a supervised setting among individuals with alcohol abuse or dependence regarding short term abstinence, days until relapse and number of drinking days, it should be noted that receipt of methadone was…”
ResultDrug Repurposing of the Alcohol Abuse Medication Disulfiram as an Anti-Parasitic Agent
Shirley, D.-A., Sharma, I., Warren, C. A., & Moonah, S. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.633194 · Cited by 47
“In case of intolerance, the dose of disulfiram can be lowered (Børup et al., 1992; Brar et al., 2004; Skinner et al., 2014).”
BackgroundBaclofen for alcohol use disorder
Agabio, R., Saulle, R., Rösner, S., & Minozzi, S. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012557.pub3 · Cited by 75
Morley, K. C., Perry, C. J., Watt, J., Hurzeler, T. P., Leggio, L., Lawrence, A. J., & Haber, P. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1892641 · Cited by 48
“In addition to modulating dopamine release and motivation [15], these changes can also lead to increased anxiety and craving for alcohol, particularly during withdrawal [13].”
BackgroundMelbourne, J. K., Thompson, K. R., Peng, H., & Nixon, K. (2019) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2019.06.011 · Cited by 41
The “First Hit” Toward Alcohol Reinforcement: Role of Ethanol Metabolites
Israel, Y., Quintanilla, M. E., Karahanian, E., Rivera‐Meza, M., & Herrera‐Marschitz, M. (2015) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12709 · Cited by 45
“Recent placebo-controlled clinical work and metaanalyses also show that disulfiram—as a drug (in blind studies)—is not different from placebo in reducing EtOH relapse in alcoholics (Skinner et al., 2014; Yoshimura et al., 2014).”
Medications for treating alcohol use disorder: A narrative review
Kranzler, H. R., & Hartwell, E. E. (2023) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.15118 · Cited by 59
Donroe, J. H., & Edelman, E. J. (2022) · Annals of Internal Medicine · doi:10.7326/aitc202210180 · Cited by 50
Cohen, S. M., Alexander, R. S., & Holt, S. R. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.08.003 · Cited by 59
Structural and mechanistic insights into the Artemis endonuclease and strategies for its inhibition
Yosaatmadja, Y., Baddock, H. T., Newman, J. A., Bielinski, M., Gavard, A. E., Mukhopadhyay, S. M. M., Dannerfjord, A. A., Schofield, C. J., McHugh, P. J., & Gileadi, O. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab693 · Cited by 42
“Disul-firam is a known acetaldehyde dehydrogenase inhibitor used in treatment for alcohol abuse disorder (89).”
Applications of Pueraria lobata in treating diabetics and reducing alcohol drinking
Liu, J., Shi, Y., & Lee, D. Y. W. (2019) · Chinese Herbal Medicines · doi:10.1016/j.chmed.2019.04.004 · Cited by 40
“The toxic reaction with alcohol can be frightening and as such it may be useful only in short-term treatment with careful monitoring (Skinner et al, 2014) as 87% of treatments were stopped at (or before) the expiration of the first prescription (Pedersen et al, 2011).”
BackgroundChaignot, C., Weill, A., Ricordeau, P., & Alla, F. (2015) · Therapies · doi:10.2515/therapie/2015027 · Cited by 39
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments
Prince, D. S., Nash, E., & Liu, K. (2023) · Drugs · doi:10.1007/s40265-023-01939-9 · Cited by 46
Outcomes of deep brain stimulation surgery for substance use disorder: a systematic review
Hassan, O., Phan, S., Wiecks, N., Joaquin, C., & Bondarenko, V. (2020) · Neurosurgical Review · doi:10.1007/s10143-020-01415-y · Cited by 38
“Disulfiram was the first FDA-approved drug for alcohol use disorder that is commonly prescribed because of its efficacy, but it has neuropsychiatric adverse effects along with hepatic and cardiac adverse effects [58].”
BackgroundBrewer, C. L., Streel, E., & Skinner, M. D. (2016) · Alcohol and Alcoholism · doi:10.1093/alcalc/agw093 · Cited by 40
Self-citationFawal, G. F. E., Abu-Serie, M. M., El‐Gendi, H., & El‐Fakharany, E. M. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.01.145 · Cited by 35
Drug Repurposing of Metabolic Agents in Malignant Glioma
Seliger, C., & Hau, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092768 · Cited by 38
“After intake of disulfiram, patients experience flu-like symptoms when they drink alcohol, because the drug inhibits the aldehyde dehydrogenase (ALDH) [101].”
BackgroundPharmacotherapies and Personalized Medicine for Alcohol Use Disorder: A Review
Lohoff, F. W. (2020) · Pharmacogenomics · doi:10.2217/pgs-2020-0079 · Cited by 41
Ketamine Treatment for Alcohol Use Disorder: A Systematic Review
Kelson, M., Burnett, J. M., Matthews, A., & Juneja, T. (2023) · Cureus · doi:10.7759/cureus.38498 · Cited by 42
“Disulfiram is an aldehyde dehydrogenase inhibitor that has limited evidence supporting its efficacy in the treatment of AUD [14,15,17].”
BackgroundTargeting Unmet Clinical Needs in the Treatment of Alcohol Use Disorder
Lohoff, F. W. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.767506 · Cited by 43
Impact of Substance Use Disorder Pharmacotherapy on Executive Function: A Narrative Review
Butler, K., & Foll, B. L. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00098 · Cited by 38
Harris, A. H. S., Weisner, C. M., Chalk, M., Capoccia, V., Chen, C., & Parks, C. L. (2016) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000203 · Cited by 33
“Using these criteria, the following medications are included in the measure specifications: naltrexone (oral and injectable), acamprosate, disulfiram, and topiramate (Maisel et al., 2013; Blodgett et al., 2014; Jonas et al., 2014; Skinner et al., 2014).”
BackgroundEvaluation and Management of Alcohol use Disorder among Older Adults
Joshi, P., Duong, K. T., Trevisan, L. A., & Wilkins, K. M. (2021) · Current Geriatrics Reports · doi:10.1007/s13670-021-00359-5 · Cited by 37
van den Brink, W., & Kiefer, F. (2020) · doi:10.1093/med/9780198713005.003.0050 · Cited by 32
Diagnosis and Management of Alcohol Use Disorder in Patients with Liver Disease: Lights and Shadows
Addolorato, G., Vassallo, G. A., Mirijello, A., & Gasbarrini, A. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00802-8 · Cited by 30
“However, only open-label trials showed a significant superiority over controls while RCTs with blind designs showed no efficacy of disulfiram [60].”
BackgroundGhin, F., Beste, C., & Stock, A. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.12.031 · Cited by 34
Outpatient management of alcohol-related liver disease
Simonetto, D. A., Shah, V. H., & Kamath, P. S. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30415-7 · Cited by 32
“Although disulfiram may be effective in preventing alcohol relapse by producing an aversive reaction when combined with alcohol, results from clinical trials have been conflicting(66, 67), and its use can lead to drug-induced liver injury with significant mortality risk.”
BackgroundHuman pharmacology for addiction medicine
Quednow, B. B., & Herdener, M. (2015) · Progress in brain research · doi:10.1016/bs.pbr.2015.07.017 · Cited by 27
“While an early review suggested superiority of disulfiram treatment for alcohol dependence compared to control conditions (Agosti, 1995), other systematic reviews reported no superiority against placebo, at least under blinded conditions (Skinner et al., 2014).”
BackgroundBoness, C. L., & Witkiewitz, K. A. (2023) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000613 · Cited by 36
Oldfield, B. J., McGinnis, K. A., Edelman, E. J., Williams, E. C., Gordon, A. J., Akgün, K. M., Crystal, S., Fiellin, L. E., Gaither, J. R., Goulet, J. L., et al. (2019) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.11.002 · Cited by 28
Factors Associated with Relapses in Alcohol and Substance Use Disorder
Yazıcı, A. B., & Bardakçı, M. R. (2023) · Eurasian Journal of Medicine · doi:10.5152/eurasianjmed.2023.23335 · Cited by 42
Stokłosa, I., Więckiewicz, G., Stokłosa, M., Piegza, M. J., Pudło, R., & Gorczyca, P. W. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20031870 · Cited by 37
“However, double-blind studies have not confirmed its greater efficacy compared with control groups [33].”
BackgroundA Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder
Celik, M., Gold, M. S., & Fuehrlein, B. (2024) · Brain Sciences · doi:10.3390/brainsci14030294 · Cited by 25
“In a meta-analysis of 22 studies, disulfiram demonstrated a higher success rate in promoting abstinence compared to placebo in open-label trials [52].”
MethodAntonelli, M., Sestito, L., Tarli, C., & Addolorato, G. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.05.016 · Cited by 28
Tran, S., Facciol, A., & Gerlai, R. T. (2016) · International review of neurobiology · doi:10.1016/bs.irn.2016.02.016 · Cited by 25
Lafi, Z., Alshaer, W., Gharaibeh, L. F., Alqudah, D. A., AlQuaissi, B., Bashaireh, B., & Ibrahim, A. A. (2023) · PLoS ONE · doi:10.1371/journal.pone.0291981 · Cited by 28
“Disulfiram (Tetra-ethyl-Disulfane dicarboamide) is an aldehyde dehydrogenase enzyme (ALDH) inhibitor that has been used for alcohol abuse for more than 60 years [28].”
BackgroundHuhn, A. S., Hobelmann, J. G., Ramirez, A., Strain, E. C., & Oyler, G. A. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.107694 · Cited by 24
Rivera‐Meza, M., Muñoz, D., Jerez, E., Quintanilla, M. E., Salinas‐Luypaert, C., Fernández, K., & Karahanian, E. (2017) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2017.00133 · Cited by 25
“Recent placebo-controlled clinical work and meta-analyses also show that disulfiram—as a drug (in blind studies)—is not different from placebo in reducing ethanol relapse in alcoholics (Skinner et al., 2014; Yoshimura et al., 2014).”
BackgroundSobering Perspectives on the Treatment of Alcohol Use Disorder
Yaseen, W., Mong, J., & Zipursky, J. S. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.3340 · Cited by 22
Bhardwaj, A., Sousa, J., Huskamp, H. A., Busch, A. B., Kennedy‐Hendricks, A., Hodgkin, D., Horgan, C. M., & Uscher‐Pines, L. (2023) · The Annals of Family Medicine · doi:10.1370/afm.2997 · Cited by 25
Pharmacotherapies for the Treatment of Alcohol Use Disorders During Pregnancy: Time to Reconsider?
Kelty, E. A., Terplan, M., Greenland, M., & Preen, D. B. (2021) · Drugs · doi:10.1007/s40265-021-01509-x · Cited by 30
Agabio, R., López‐Pelayo, H., Bruguera, P., Huang, S., Sardo, S., Peciña, M., Krupitsky, E. M., Fitzmaurice, G. M., & Lin, Z. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107454 · Cited by 26
Botwright, S., Sutawong, J., Kingkaew, P., Anothaisintawee, T., Dabak, S. V., Suwanpanich, C., Promchit, N., Kampang, R., & Isaranuwatchai, W. (2023) · BMC Public Health · doi:10.1186/s12889-023-15152-6 · Cited by 24
Popova, D., Gameiro‐Ros, I., Youssef, M. M., Zalamea, P. D., Morris, A., Prytkova, I., Jadali, A., Kwan, K. Y., Kamarajan, C., Salvatore, J. E., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01818-x · Cited by 21
Pharmacogenetics of alcohol use disorders and comorbid psychiatric disorders
Helton, S. G., & Lohoff, F. W. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.09.019 · Cited by 22
“In fact, patients prescribed disulfiram reported significantly more adverse events than controls (Skinner et al., 2014).”
BackgroundPeniche, A. G., Renslo, A. R., Melby, P. C., & Travi, B. L. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05131-14 · Cited by 23
Animal models of alcohol use disorder and the brain: From casual drinking to dependence.
Crowley, N. A., Dao, N. C., Magee, S. N., Bourcier, A. J., & Lowery‐Gionta, E. G. (2019) · Translational Issues in Psychological Science · doi:10.1037/tps0000198 · Cited by 17
Advancing Pharmacotherapy Development from Preclinical Animal Studies
Egli, M. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2017_85 · Cited by 19
Tracing the journey of disulfiram: From an unintended discovery to a treatment option for alcoholism
Pattanayak, R., Sagar, R., & Pal, A. (2015) · Journal of Mental Health and Human Behaviour · doi:10.4103/0971-8990.164826 · Cited by 20
Disulfiram for binge eating disorder: An open trail
Farci, A. M. G., Piras, S., Murgia, M., Chessa, A., Restivo, A., Gessa, G. L., & Agabio, R. (2014) · Eating Behaviors · doi:10.1016/j.eatbeh.2014.10.008 · Cited by 22
Merrill, J. O., & Duncan, M. H. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.06.008 · Cited by 45
Ashraf, F., Zareen, G., & Yıldırım, M. (2023) · Journal of Religion & Spirituality in Social Work Social Thought · doi:10.1080/15426432.2023.2167255 · Cited by 43
“Such experiences shape them in that particular environmental context (Skinner et al., 2014).”
BackgroundSaitoh, A., Nagayama, Y., Yamada, D., Makino, K., Yoshioka, T., Yamanaka, N., Nakatani, M., Takahashi, Y., Yamazaki, M., Shigemoto, C., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.826783 · Cited by 19
“Today, DSF is used as a useful treatment option for those suffering from alcoholism (Skinner et al., 2014).”
BackgroundHo, A. L., Feng, A. Y., Barbosa, D. A. N., Wu, H., Smith, M. L., Malenka, R. C., Tass, P. A., & Halpern, C. H. (2021) · Brain stimulation · doi:10.1016/j.brs.2021.01.015 · Cited by 19
Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder
Köhne, S., Hillemacher, T., Glahn, A., & Bach, P. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2342951 · Cited by 22
“Blinded trials found no significant benefit for disulfiram [34].”
Metadata
- Authors
- Skinner, M. D., Lahmek, P., Pham, H., & Aubin, H.-J.
- Affiliations
- Inserm (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Université Paris-Sud (FR)
- Corresponding author
- Skinner, Marilyn D.
- ORCID
- Aubin, Henri-Jean
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-02-10
- Volume
- 9
- Issue
- 2
- Pages
- e87366
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3919718
- OpenAlex
- W2135168571
- Cited by
- 347
- References
- 71
- Citations by year
- 2026: 24 · 2025: 21 · 2024: 43 · 2023: 51 · 2022: 28 · 2021: 31 · 2020: 26 · 2019: 37 · 2018: 23 · 2017: 18 · 2016: 23 · 2015: 20 · 2014: 2
- FWCI
- 2.76
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Clinical Neurology › Alcoholism and Thiamine Deficiency
- Keywords
- disulfiram, alcoholism, alcoholism treatment, abstinence, naltrexone, acamprosate, supervised treatment, cocaine use, treatment efficacy, drug safety
- MeSH terms
- Adolescent, Adult, Aged, Alcohol Deterrents, Alcoholism, Cocaine, Disulfiram, Female, Humans, Male, Middle Aged, Case-Control Studies, Randomized Controlled Trials as Topic, Treatment Outcome, Endpoint Determination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.